Early Access Programs & Named Patient Supply

Our company specializes in Early Access Programs (EAP) and Named Patient Supply (NPS), enabling patients and healthcare professionals to access innovative therapies before they become commercially available in their country. Through structured Early Access Programs, we facilitate the ethical and compliant provision of investigational or pre-approved medicines to patients with serious or life-threatening conditions who have no satisfactory treatment alternatives. We collaborate closely with pharmaceutical companies, healthcare providers, and regulatory authorities to ensure that access pathways are managed efficiently and in full compliance with applicable regulations.

We also manage Named Patient Supply, allowing physicians to request specific medicines for individual patients when those treatments are not yet authorized or available in their market. Our team coordinates the entire process, including regulatory compliance, documentation, importation, and secure logistics. In Switzerland, under Article 49 of the Swiss Therapeutic Products Act (TPA), we facilitate managed access programs and named patient supply, providing early access to innovative therapies for patients with life-threatening or severely debilitating diseases.

By combining regulatory expertise, operational efficiency, and a strong commitment to patient access, we help bridge the gap between medical innovation and patients in need.